Spark layoffs won't derail Philadelphia's biotech surge, city official says
Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics.
Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large.
'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Technical.ly Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.'
Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene.
From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors.
'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said.
Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia.
Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative.
'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Technical.ly
09-05-2025
- Technical.ly
Spark layoffs won't derail Philadelphia's biotech surge, city official says
Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics. Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large. 'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.' Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene. From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors. 'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said. Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia. Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative. 'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
Technical.ly
04-04-2025
- Technical.ly
Spark Therapeutics files notice to lay off 300 employees this year
Cell and gene therapy standout Spark Therapeutics is undergoing its second shakeup in a month, with plans to lay off about half of its workforce. Several hundred people will be affected. A WARN notice, which companies file to provide advance notice of layoffs, reported 298 eliminated positions in the Philadelphia region. A Spark Therapeutics spokesperson told the Philadelphia Business Journal on Thursday it would be laying off 337 of its almost 650 employees. These changes are expected to occur in three waves: in May, July and at the end of 2025. The remaining 310 employees will be incorporated into parent company Roche, a multinational pharmaceutical company. Spark first announced on January 30 the decision to integrate more of its work into Roche, spokesperson Denise Bradley told The impacted employees will be eligible for severance, outplacement services and will be able to apply for other roles within Roche. Spark's plans for its University City-based Gene Therapy Innovation Center in Philadelphia have not changed, Bradley said. Last month, Roche classified the former startup as a financial loss following the end of its trial for a hemophilia A gene therapy treatment, the Philadelphia Inquirer reported. The company is still working on a new Hemophilia A gene product, Spark previously told The layoff announcement comes less than a year after Spark's previous workforce reduction, when it let less than 50 of its employees go in July 2024. At the end of last year, the company welcomed Roche veteran Sylke Poehling as its new CEO, replacing Ron Phillip, who had been in the role since 2022. Spark's year of downsizing Recent struggles at Spark, which was founded by Jeffrey Marrazzo in 2013 and was considered a big Philadelphia success story, indicate the need for the gene therapy sector to make manufacturing more cost effective, Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce, previously told But the company itself heavily contributed to the development of the industry as a whole. 'They really created a lot of recognition for gene therapy and innovation,' Grant said. 'Now more people understand what gene therapy means and how it can literally cure disease.' In 2021, the company announced plans for a 500,000-square-foot Gene Therapy Innovation Center in University City. At the time, Spark said the new site would house over 500 jobs. The Innovation Center is still expected to be completed next year, Spark spokesperson Bradley previously told The Penn spinout is known for developing the first FDA-approved gene therapy, Luxturna. Pharma giant Roche acquired Spark in 2019 for $4.8 billion, the largest VC-backed exit in Philadelphia at the time. 'Gene therapy is not a huge sector, and Spark was a trailblazer,' Dean Miller, president of the Philadelphia Alliance for Capital and Technologies, previously said. '[It's] never easy when your trailblazer starts to disappear a little further.' Sarah Huffman is a 2022-2024 corps member for Report for America, an initiative of The Groundtruth Project that pairs young journalists with local newsrooms. This position is supported by the Lenfest Institute for Journalism.
Technical.ly
04-04-2025
- Technical.ly
Philly founder proves the maxim ‘Your net worth is your network'
Simone Ammons built software startup QuneUp with about $140,000 from a side gig. Now, she's growing it through the power of community. Ammons launched her company with funds she made from working as a technical writer. Still bootstrapped, Ammons mostly relies on her strong network to keep it growing. That goes hand in hand with her dedication to uplifting others along the way, she told reporter Sarah Huffman on Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. 'Everything about QuneUp … was partnered with somebody else in the community that looked like me,' Ammons said, referencing how she connected with the 'fraction of a percent' of other Black women in the business community. Philly-based QuneUp, started in 2022, began with Ammon's personal frustration at work. As an engineer, every time equipment broke down, she got the call to fix it. The equipment often lacked vital information, like the vendor or when it was installed. In response, she developed a QR code sticker that takes the technician to the equipment landing page with all the information needed for repairs. Featured as an honorable mention in 2025 RealLIST Startups, QuneUp has also been recognized with valuable support from other respected institutions, including at two pitch competitions supported by the Philadelphia Department of Commerce. In 2024, QuneUp came in third place, taking home a $2,000 prize and the year prior, it was a finalist in Philly's Most Diverse Tech Hub Pitch Competition. It was also a member of the December 2023 Capital Readiness Program session run by the University City Science Center and, most recently, selected for the inaugural cohort of biotech accelerator HiveBio. Those connections also gave her the platform to find new customers, Ammons said, crediting the Department of Commerce for helping her land two pilots. Plus, it acted as a 'mini MBA' to learn how to run a business beyond just building the software, Ammons said. 'What I realized in business is that your net worth is your network,' Ammons said. Being a part of the community means she's just '10 conversations away from somebody who is interested in investing in a company like mine.'
